UPDATE: Jefferies Starts Acceleron Pharma (XLRN) at Hold

October 6, 2021 4:13 PM EDT
Get Alerts XLRN Hot Sheet
Price: $178.75 --0%

Rating Summary:
    11 Buy, 11 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 5 | Down: 13 | New: 15
Join SI Premium – FREE
(Updated - October 6, 2021 4:14 PM EDT)

Jefferies analyst Akash Tewari initiates coverage on Acceleron Pharma (NASDAQ: XLRN) with a Hold rating and a price target of $180.00.

The analyst comments "On 9/30 MRK entered into an agreement to acquire XLRN for $180/cash (~$11.5Bn mkt cap). While we do think the deal holds, we believe MRK got a great deal given the upside for Sotatercept in PAH which we think is a $3-5Bn+ opportunity. Our report goes in depth on the upcoming STELLAR trial. Additionally, we think Reblozyl will work in 1L MDS and continue to generate a sig. and growing royalty stream for XLRN. Hold, $180 PT."

For an analyst ratings summary and ratings history on Acceleron Pharma click here. For more ratings news on Acceleron Pharma click here.

Shares of Acceleron Pharma closed at $177.13 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Jefferies & Co, Definitive Agreement